MarketPeel
Insider Trading Intelligence
Pricing
…
JS

Jason Drew Smith

URGN
GENERAL COUNSEL · UROGEN PHARMA LTD. · CIK 0001821479
FILING MIX · LIFETIME47%/53%
BUYS
34
SELLS
38
TOTAL VALUE
$778.9K
COMPANIES
1
ACTIVE SINCE
Sep 2020
HOLDINGS NOW
55,588
AVG SELL PX
$15.20
TRADE KIND
SHOWING 72 / 72
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
22 backtested trades · 8 horizons · 17 pending
Forward-return performance of every backtestable P/S trade by Jason Drew Smith, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d22+50.00%+2.13%+1.20%+0.93%-1.11%—
14d22+54.55%+3.54%+1.32%+2.22%+0.32%—
30d22+63.64%-2.08%+0.79%-2.87%+0.45%—
60d22+81.82%-5.61%+1.14%-6.74%-9.88%—
90d22+45.45%-0.23%+1.80%-2.03%-1.88%—
180d22(3 pending)+36.84%+22.54%+7.86%+14.68%-7.07%—
1y22(5 pending)+47.06%+16.04%+16.87%-0.83%-19.96%—
2y22(9 pending)+0.00%+26.79%+37.27%-10.49%-20.67%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
URGN · 55,588 shares · as of Feb 3, 2026
015,00030,00045,00060,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 34 buys / 38 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
2,654$19.69$52.3K52,934Feb 3, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
1,608$19.69$31.7K51,326Feb 3, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,217$19.69$63.3K55,588Feb 3, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
6,667——49,972Jan 31, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
6,667——0Jan 31, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
5,500——5,500Jan 31, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
5,500——55,472Jan 31, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
3,333——58,805Jan 31, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,333——6,667Jan 31, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
32,609——32,609Jan 31, 2026Feb 11, 2026 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
1,520$19.11$29.0K43,305Sep 8, 2025Sep 9, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
3,333——44,825Sep 7, 2025Sep 9, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,333——3,334Sep 7, 2025Sep 9, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
7,522$19.14$144.0K41,492Jul 28, 2025Jul 30, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
16,500——49,014Jul 28, 2025Jul 30, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,354$11.14$37.4K29,781Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
2,767$11.14$30.8K32,514Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
6,667——33,135Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
5,500——35,281Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
2,500——0Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
6,667——6,667Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
10,000——10,000Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
5,500——11,000Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
2,500——27,726Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
1,258$11.14$14.0K26,468Jan 31, 2025Feb 4, 2025 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,333——6,667Sep 9, 2024Sep 12, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
1,521$13.08$19.9K25,226Sep 9, 2024Sep 12, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
3,333——26,747Sep 9, 2024Sep 12, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,328$15.78$52.5K23,414Feb 1, 2024Feb 5, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
1,248$15.78$19.7K20,076Feb 1, 2024Feb 5, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
417$15.78$6.6K18,824Feb 1, 2024Feb 5, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
1,248$15.74$19.6K20,076Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,328$15.74$52.4K23,414Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
834——19,241Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
417$15.74$6.6K18,824Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
6,666——26,742Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
834——0Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
16,500——16,500Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
6,666——13,334Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
2,500——2,500Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
2,500——21,324Jan 31, 2024Feb 2, 2024 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
10,000——10,000Sep 7, 2023Sep 8, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
8,334——0Aug 31, 2023Sep 5, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,800$18.01$68.4K18,407Aug 31, 2023Sep 5, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
8,334——22,207Aug 31, 2023Sep 5, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
1,227$10.12$12.4K13,873Jan 31, 2023Feb 2, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
40,000——40,000Jan 31, 2023Feb 2, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
20,000——20,000Jan 31, 2023Feb 2, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
409$10.12$4.1K12,600Jan 31, 2023Feb 2, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
2,500——5,000Jan 31, 2023Feb 2, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
833——13,009Jan 31, 2023Feb 2, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
833——834Jan 31, 2023Feb 2, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
2,500——15,100Jan 31, 2023Feb 2, 2023 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,606$7.21$26.0K12,176Aug 31, 2022Sep 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
8,333——8,334Aug 31, 2022Sep 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
8,333——15,782Aug 31, 2022Sep 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
30,000——30,000Jan 31, 2022Feb 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
7,500——7,500Jan 31, 2022Feb 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
414$7.58$3.1K7,449Jan 31, 2022Feb 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
833——7,863Jan 31, 2022Feb 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
833——1,667Jan 31, 2022Feb 1, 2022 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
8,333——16,667Nov 30, 2021Dec 2, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
SALE
General Counsel
3,803$12.03$45.8K7,030Nov 30, 2021Dec 2, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
8,333——10,833Nov 30, 2021Dec 2, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
15,000——15,000Jun 5, 2021Jun 8, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASE
General Counsel
2,500$15.71$39.3K2,500May 17, 2021May 17, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
8,000——8,000Jan 31, 2021Feb 2, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
2,500——2,500Jan 31, 2021Feb 2, 2021 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
60,000——60,000Oct 1, 2020Oct 2, 2020 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
25,000——25,000Oct 1, 2020Oct 2, 2020 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
25,000——25,000Sep 9, 2020Sep 10, 2020 ↗View →
URGN
UROGEN PHARMA LTD.
PURCHASEGRANT
Stock grant
60,000——60,000Sep 9, 2020Sep 10, 2020 ↗View →
Other insiders · URGN
Loading peer insiders…
About this filer
CIK 0001821479
ROLE
General Counsel
PRIMARY
URGN
COMPANIES
1
ACTIVE SINCE
Sep 2020
MARKETPEEL · /INSIDER/0001821479DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback